Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Forecast & Target Price

View the latest analyst price targets and forecasts to stay informed on market expectations. Click here to open.

MGX

Metagenomi Inc

Dec 02 • 04:00PM ET

2.08

Dollar change +0.01
Percentage change 0.48	%

Healthcare • Biotechnology • USA • NASD

Peers: NTLA CRSP EDIT BEAM VERV PRME DNLI VRTX SGMO ARCT

| Held by: VTI IWM VXF IWO IWN VTWO IWC RSSL VTWG VTWV

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.50	Insider Own	49.81%	Shs Outstand	37.43M	Perf Week	10.05%
Market Cap	79.77M	Forward P/E	-	EPS next Y	-2.66	Insider Trans	-0.03%	Shs Float	18.78M	Perf Month	5.58%
Income	-73.95M	PEG	-	EPS next Q	-0.75	Inst Own	25.17%	Short Float	2.36%	Perf Quarter	-28.03%
Sales	55.08M	P/S	1.45	EPS this Y	87.64%	Inst Trans	-4.50%	Short Ratio	1.29	Perf Half Y	-68.91%
Book/sh	6.83	P/B	0.30	EPS next Y	-7.44%	ROA	-19.86%	Short Interest	0.44M	Perf Year	-
Cash/sh	7.16	P/C	0.29	EPS next 5Y	-	ROE	-30.34%	52W Range	1.61 - 12.74	Perf YTD	-79.83%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-24.89%	52W High	-83.67%	Beta	-
Dividend TTM	-	Quick Ratio	6.18	Sales past 5Y	3569.20%	Gross Margin	90.66%	52W Low	29.19%	ATR (14)	0.17
Dividend Ex-Date	-	Current Ratio	6.18	EPS Y/Y TTM	-	Oper. Margin	-160.63%	RSI (14)	55.04	Volatility	7.14% 9.46%
Employees	236	Debt/Eq	0.18	Sales Y/Y TTM	-	Profit Margin	-134.27%	Recom	1.29	Target Price	17.00
Option/Short	No / Yes	LT Debt/Eq	0.16	EPS Q/Q	3.46%	Payout	-	Rel Volume	1.16	Prev Close	2.07
Sales Surprise	70.35%	EPS Surprise	34.26%	Sales Q/Q	-6.87%	Earnings	Nov 13 AMC	Avg Volume	343.92K	Price	2.08
SMA20	5.26%	SMA50	3.89%	SMA200	-61.31%	Trades		Volume	398,534	Change	0.48%

Date	Action	Analyst	Rating Change	Price Target Change
May-07-24	Initiated	H.C. Wainwright	Buy	$10
May-02-24	Downgrade	JP Morgan	Overweight → Neutral	$16 → $6
Mar-05-24	Initiated	Wells Fargo	Overweight	$25
Mar-05-24	Initiated	TD Cowen	Outperform
Mar-05-24	Initiated	JP Morgan	Overweight	$16
Mar-05-24	Initiated	Jefferies	Buy	$23
Mar-05-24	Initiated	Chardan Capital Markets	Buy	$21
Mar-05-24	Initiated	BMO Capital Markets	Outperform	$22

Nov-18-24 12:00PM	What Makes Metagenomi (MGX) a New Buy Stock (Zacks)
Nov-13-24 04:37PM	Metagenomi: Q3 Earnings Snapshot (Associated Press Finance) -10.90%
04:05PM	Metagenomi Reports Business Updates and Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-05-24 04:05PM	Metagenomi To Present New Preclinical Hemophilia A Data at American Society of Hematology (ASH) 66th Annual Meeting (GlobeNewswire)
Oct-29-24 05:45AM	Metagenomi, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before November 25, 2024 to Discuss Your Rights - MGX (PR Newswire)
08:04AM	Loading…
Oct-24-24 08:04AM	Metagenomi Presents Novel, Highly Specific and Efficient Adenine Base Editors for Broad Genome Editing at ESGCT (GlobeNewswire)
Oct-23-24 05:45AM	Investors in Metagenomi, Inc. Should Contact Levi & Korsinsky Before November 25, 2024 to Discuss Your Rights - MGX (PR Newswire)
Oct-14-24 08:58PM	Metagenomi Presents Compact SMART Editing Platform at AIChE 7th International Conference on CRISPR Technologies (GlobeNewswire)
Oct-01-24 03:14PM	Metagenomi, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 25, 2024 to Discuss Your Rights - MGX (PR Newswire)
Sep-19-24 07:15PM	Metagenomi to Present at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire) -6.84%
Sep-03-24 04:05PM	Metagenomi Announces Preclinical Data for Lead Hemophilia A Program Demonstrating Durable Factor VIII (FVIII) Activity Levels through Twelve Months (GlobeNewswire)
Aug-29-24 07:32PM	Metagenomi Presents AI-Enabled Advancements of SMART Editing Platform at the Cold Spring Harbor Laboratory CRISPR Frontiers Conference (GlobeNewswire)
Aug-28-24 06:10PM	Metagenomi to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.05%
Aug-26-24 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Metagenomi, Target Hospitality, Helios, and LegalZoom and Encourages Investors to Contact the Firm (GlobeNewswire)
Aug-14-24 08:11AM	Metagenomi: Q2 Earnings Snapshot (Associated Press Finance)
08:05AM	Loading…
08:05AM	Metagenomi Reports Business Updates and Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-12-24 06:29PM	Metagenomi, Inc. (MGX): This New Penny Stock Received a Positive Rating From Street Analysts (Insider Monkey) +10.54%
Aug-05-24 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Dril-Quip, LPL Financial, Methode, and Metagenomi and Encourages Investors to Contact the Firm (GlobeNewswire)
Jun-03-24 04:30PM	Is Moderna Inc. (NASDAQ:MRNA) the Top Gene Therapy Stock to Invest in Now? (Insider Monkey)
04:17PM	9 Best Gene Therapy Stocks to Buy Now (Insider Monkey)
May-29-24 04:00PM	Metagenomi to Present at the 2024 Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-24 10:54PM	MGX Stock Earnings: Metagenomi Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:05PM	Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results (GlobeNewswire)
May-04-24 10:49AM	Moderna, Inc. (NASDAQ:MRNA) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-02-24 06:04AM	3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire (InvestorPlace) -12.36%
May-01-24 04:00PM	Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems (GlobeNewswire)
01:53PM	Moderna exits gene editing deal worth up to $3B biobucks, leaving Metagenomi in the spotlight (FierceBiotech.com)
Apr-08-24 08:00AM	Metagenomi to Present at Upcoming Scientific Meetings (GlobeNewswire)
Mar-27-24 09:16AM	Metagenomi Reports Business Updates and Full Year 2023 Financial Results (GlobeNewswire)
Feb-29-24 04:30PM	Metagenomi to Participate in the 44th Annual Cowen Healthcare Conference (GlobeNewswire)
04:35PM	Loading…
Feb-13-24 04:35PM	Metagenomi Announces Closing of Initial Public Offering (GlobeNewswire)
Feb-08-24 10:16PM	Metagenomi Announces Pricing of Initial Public Offering (GlobeNewswire)

Metagenomi, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. Its business activities include developing gene edit-ing toolbox, ther-a-peu-tic focus, and processing discovery platform. The company was founded by Brian C. Thomas on September 16, 2016 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wapnick Pamela	Chief Financial Officer	Sep 05 '24	Sale	2.88	6,265	18,043	63,051	Sep 06 05:14 PM
Novo Holdings A/S	10% Owner	Feb 13 '24	Buy	15.00	800,000	12,000,000	1,739,175	Feb 15 08:38 PM
Novo Holdings A/S	10% Owner	Feb 09 '24	Buy	10.25	100,000	1,025,000	100,000	Feb 15 08:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MGX

Metagenomi Inc

Upgrade your FINVIZ experience